Due to fedratinib's significant GI side effect profile and the logistical difficulty of measuring thiamine levels, clinicians should proactively provide patients with thiamine supplements, anti-emetics, and anti-diarrheal therapies. Instructing patients to take the drug with food can also help mitigate GI toxicity.

BTK inhibitors function as highly potent antiplatelet agents, an 'on-target' effect. Many surgeons are unaware, leading to significant post-operative bleeding if the drug isn't stopped. Patients must be educated to inform their surgical teams and advocate for themselves.

Concerns over arterial events caused physicians to start CML patients on lower, less effective doses of ponatinib. Data shows a start-high (45mg) then reduce strategy is more effective for disease control and safely mitigates side effect risks, contrary to clinical practice.

The dangerous nitrosamine (NDMA) in Zantac wasn't a pre-existing manufacturing contaminant. The active drug, ranitidine, chemically degraded to form the carcinogen. This finding, which corrected the FDA's initial assessment, shows that a drug itself can be the source of its own toxicity, a critical distinction for risk analysis.

Alternate TKI formulations, like nilotinib, are engineered to be superior to parent compounds. They remove dietary restrictions (fasting) and interference from acid reducers, ensuring consistent drug exposure. This can reduce adverse effects and improve patient quality of life, moving beyond the simple 'biosimilar' label.

BTK inhibitors block B-cell receptor signaling, causing long-surviving CLL cells to undergo programmed cell death (apoptosis) from a lack of stimulation. The common side effects are due to off-target kinase inhibition, not the intended BTK blockade itself, which has negligible action on other cells.

When patients experience side effects from a regimen with multiple oral drugs on different schedules, there is a high risk of confusion. A patient may hold the wrong medication, leading to uncontrolled side effects and delayed management, highlighting the need for clear communication.

Contrary to the assumption that combinations are more toxic, Lenvatinib/Belzutifan showed a different side effect profile, not a worse one, compared to single-agent Cabozantinib. The combo caused more anemia while Cabozantinib caused more diarrhea and skin toxicity, but treatment discontinuation rates were identical at 11% for both arms.

Newer TKI formulations ensure consistent drug absorption, correcting for under-dosing caused by food or other medications. While improving efficacy, this means more patients may experience the drug's known side effects. What seems like new toxicity could be the drug’s true profile, no longer masked by poor absorption.